Health Condition 1: null- Lung cancer patients having chronic cough more than 2 weeks, on cough suppressant as per treating physician choice
Conditions
Interventions
Intervention1: Aprepitant: Dose: Aprepitant 125 mg
Frequency: Daily 1 tab
On day 1 125mg, Day 2 to Day 7 80 mg + treatment of choice of physician
Route of administration: Oral Tablet
Control Interv
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male or female patients aged 18 years or older 2.Lung cancer patients with advanced stage 3.Having chronic cough more than 2 weeks, and on regular cough suppressant. 4.ECOG performance score 0-2 5.Able to give informed consent 6.Willing to follow the trial related activities
Exclusion criteria
Exclusion criteria: 1.ECOG performance score >= 3 2.Patient receiving aprepitant . 3.Patient using pimozide for psychiatric illness, as aprepitant increases level of pimozide by decreaing metabolism, causes life threatening QT prolongation. 4.As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease) 5.Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effect of Aprepitant on subjective improvement in cough measured by Visual analogue scales(VAS), Manchester cough in lung cancer scale (MCLCS)Timepoint: Day 0, Day 3, Day 7, Day9 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To study the effect of Aprepitant on QOL. 2. To study the side effect of the treatment Timepoint: 1. QOL at Baseline & End of Study 2. Day 0, Day 3, Day 7, Day 9 | — |
Countries
India
Contacts
Public ContactDr Sandeep Ishi
Tata MemorialHospital
Outcome results
None listed